Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer
- Pierre-Yves Berclaz joins Ferring’s Executive Committee as Executive Vice President, Chief Medical Officer
- Pierre-Yves previously held the position of Senior Vice President, Head of Global Medical Affairs for Neurology and Immunology at Merck KGaA/EMD Serono
Saint-Prex, Switzerland – 10 January 2023 – Ferring Pharmaceuticals announced today that Pierre-Yves Berclaz has joined the company as its new Executive Vice President, Chief Medical Officer.
Pierre-Yves brings extensive medical and scientific expertise to Ferring, having previously held the position of Senior Vice President, Head of Global Medical Affairs for Neurology and Immunology at Merck KGaA/EMD Serono, based in Boston, USA.
Prior to this, Pierre-Yves spent over 14 years at Eli Lilly, holding leadership roles in Medical Affairs, Global Clinical Development, Clinical Pharmacology and Discovery Research in multiple therapeutic areas, including immunology, neuroscience, diabetology and oncology. Pierre-Yves also spent seven years as Chief Medical Officer for Eli Lilly Japan, where he led the clinical and medical efforts in the successful launches of numerous new molecular entities (NMEs) and line extensions.
Per Falk, President of Ferring, commented, “I am delighted to welcome Pierre-Yves Berclaz to the Ferring family. Pierre-Yves will ensure that the needs of our patients is the foundation on how we conduct our business and continue to deliver on our purpose to help people around the world to build families and live better lives.”
Earning a medical degree from the University of Lausanne, Pierre-Yves achieved his specialty training in Paediatrics at the Universities of Lausanne and Geneva. He obtained his sub-specialty in Pulmonary Medicine and his PhD in Molecular Biology from the Cincinnati College of Medicine, where he served as Assistant Professor, Paediatric Pulmonology prior to joining Eli Lilly.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
For more information, please contact
Carine Julen
Corporate Communications Manager
+41 76 301 0178 (mobile)
+41 79 191 0632
carine.julen@ferring.com
